AtaiBeckley Inc.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion Considers Strategic Alternatives
Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening.
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by...
AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued
Eli Lilly and Company has agreed to acquire AtaiBeckley (NasdaqGM:ATAI) in a cash and contingent value rights deal valued at up to $3.8b, putting fresh focus on the stock’s risk and return trade off. See our latest analysis for AtaiBeckley. AtaiBeckley’s share price has reacted sharply to the Eli Lilly bid, with a 33.4% 1 day share price return on the announcement and an 84.75% year to date share price return. The 1 year total shareholder return of 156.27% contrasts with a 5 year total...
Eli Lilly's $3.8bn psychedelics bet is built on British science
Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a vindication of two decades of British research once dismissed as fringe science. The prize at the centre of the deal is BPL-003, a nasal spray formulation of the psychedelic...
Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today?
Apple, AtaiBeckley and UnitedHealth Group jumped to yearly highs as positive company catalysts, Wall Street upgrades, and strong earnings pushed shares higher.
AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly
AtaiBeckley climbed to a new four-year high on Thursday, as investors bought into its shares following news that Eli Lilly agreed to acquire the company for up to $3.8 billion. In intra-day trading, the stock surged to a record high of $7.22 before trimming gains to end the session just up by 33.40 percent at […]
Why AtaiBeckley Stock Soared Today
The psychedelic drugmaker is being acquired.
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.
Eli Lilly Buys AtaiBeckley in $3.8 Billion Deal
Acquisition could strengthen its neuroscience growth strategy
Congressional Trades in $ATAI
No disclosed congressional trades found in $ATAI.
Insider Trades (Form 4)
HERSHBERG ROBERT
Craig Kevin James
Kochendoerfer Gerd
Angermayer Christian
Braunstein Scott
Fischer Laurent
HERSHBERG ROBERT
Hoffman John Francis
Key People
Kochendoerfer Gerd
Chief Operating Officer
Craig Kevin James
Chief Medical Officer
Angermayer Christian
Director
HERSHBERG ROBERT
Director
Hoffman John Francis
Director
JOHNSON SABRINA MARTUCCI
Director
Kalali Amir H
Director
Fischer Laurent
Director
Braunstein Scott
Director
Smiley Andrea Heslin
Director
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro